Illinois is currently home to 2636 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Empowering Veterans to Actively Communicate and Engage in Shared Decision Making in Medical Visits, A Randomized Controlled Trial
NCT05169359
Recruiting
Type 2 diabetes is a significant condition in VA affecting 20% of VA patients. Adherence to medication regimens and lifestyle factors is important to achieve care goals for these patients. Patients who use active participatory communication behaviors with their providers have better adherence to treatment and better biomedical outcomes, yet many patients are not prepared to engage in active communication with their providers. Existing coaching interventions have not been adopted in practice beca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: Chicago Heights VA Clinic, Chicago Heights, Illinois
Conditions: Diabetes Mellitus (Type 2)
Register for Updates
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
NCT06499870
Recruiting
This phase II trial tests how well relugolix and enzalutamide, in combination with radiation therapy, works in treating patients with very high risk prostate cancer. Relugolix is a form of androgen deprivation therapy. It prevents the release of testosterone, a hormone required to sustain prostate growth. Reducing testosterone levels may inhibit the proliferation of prostate tumor cells that need testosterone to grow. Enzalutamide is an androgen receptor signaling inhibitor. It inhibits the acti... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Prostate Adenocarcinoma
Register for Updates
GU-01: Glycyrrhizin in Prostate Cancer
NCT06378346
Recruiting
This is a pilot, randomized, window-of-opportunity treatment trial in which participants with previously untreated prostate cancer (PCa) who are candidates for surgery (radical prostatectomy)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Illinois, Chicago, Illinois
Conditions: Prostate Cancer
Register for Updates
CIED Infection Quality Initiative Demonstration Project
NCT05471973
Recruiting
The aim of this Quality Initiative (QI) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (CIED) infection. Multidisciplinary teams will be established to carry out the multifaceted intervention. This program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of CIED infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Northwestern, Chicago, Illinois
Conditions: Infections
Register for Updates
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial
NCT04883671
Recruiting
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma
Register for Updates
Fisetin to Reduce Senescence and Mobility Impairment in PAD
NCT06399809
Recruiting
The investigators propose a pilot randomized trial to gather preliminary data to test the hypothesis that Fisetin will reduce abundance of senescent cells in blood, skeletal muscle, and both subcutaneous and inter muscular adipose tissue and improve 6-minute walk distance in 34 people with peripheral artery disease (PAD). the investigators will determine whether greater declines in abundance of cells with senescent markers are associated with greater improvement in 6-minute walk distance in peop... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
10/06/2024
Locations: Northwestern University Feinberg School of Medicine, Chicago, Illinois
Conditions: Peripheral Arterial Disease, Aging, Peripheral Vascular Diseases, Walking, Difficulty, Claudication
Register for Updates
Wearable Gait Sensors
NCT06628934
Recruiting
This research study is testing body-worn sensors to measure movement during simple tests of coordination, in order to evaluate the progression and severity of Spinocerebellar ataxia.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/03/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: Spinocerebellar Ataxia
Register for Updates
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
NCT05649098
Recruiting
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) the administration of dupilumab will be well-tolerated, regardless of underlying genetic skin disorder. The total clinical study duration will be 26 months (104 Weeks). The treatm... Read More
Gender:
ALL
Ages:
6 months and above
Trial Updated:
10/03/2024
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Skin Diseases
Register for Updates
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
NCT05042258
Recruiting
Single center, prospective, Open label study of sleep, pruritus and circadian function pre/post 12-weeks of dupilumab treatment in children 6-17 years old
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
10/03/2024
Locations: Lurie Children's Hospital/Northwestern University, Chicago, Illinois
Conditions: Atopic Dermatitis, Sleep Disturbance
Register for Updates
Cardioneuroablation for Recurrent Vasovagal Syncope and Bradyarrhythmias: The CNA-FWRD Registry
NCT06166277
Recruiting
The CNA-FWRD Registry is an international prospective observational multicenter registry of patients with symptomatic vasovagal syncope and bradyarrhythmias managed under routine care by medical therapy and radiofrequency catheter ablation of ganglionated plexi or permanent pacemaker implantation.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
10/02/2024
Locations: Rush University Medical Centert, Chicago, Illinois
Conditions: Vasovagal Syncope, AV Block-2Nd Degree-Type 1, Sinus Pause
Register for Updates
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
NCT06129864
Recruiting
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
10/02/2024
Locations: Research Site, Niles, Illinois
Conditions: Locally Advanced Head and Neck Squamous Cell Carcinoma
Register for Updates
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: HER2-positive Advanced Solid Tumor
Register for Updates